Salus Telehealth creates board of directors after merger

Since acquiring VideoMedicine in September, Salus Telehealth has taken steps to reorganize its leadership as the companies adjust to the new partnership.

Salus, a Waycross, Georgia-based company that designs and implements telemedicine programs, which now owns VideoMedicine, a mobile, free-market doctor network, announced the creation of a seven-member board of directors that will help guide the merged entities. The board plans to help Salus achieve its goal of reducing healthcare costs and improving patient outcomes through telemedicine.

Listed below are the seven members:

· Charles Butler, MD: Butler, the creator of VideoMedicine, will serve as chairman of the board. He is a former U.S. Olympic athlete, an entrepreneur and philanthropist. He received his MD from New York University’s School of Medicine and is board certified by the American Board of Internal Medicine.

· Bernard A. Harris Jr., MD, MBA: Harris will serve at the vice chairman for the board. He is also the CEO and managing partner of Vesalius Ventures, a Houston-based medical venture capital firm. Additionally, he was an astronaut at NASA for 10 years.

· Paula Guy: Guy serves as the president and CEO of Salus Telehealth and is a founding member of the board. She is a telemedicine expert and frequently gives speeches and offers consulting services on the topic.

· Frederick Feit, MD: In addition to his board duties, Feit is the director of the Fellowship Training Program in Interventional Cardiology and is an associate professor of medicine at the NYU Langone School of Medicine.

· Brent Furse: Furse also serves as the Global Chief Commercial Officer and President of U.S. at Cardiorentis AG, a Switzerland-based pharmaceutical company.

· David Flannery, MD: He is also the medical director at the American College of Medical Genetics and Genomics in Bethesda, Maryland.

· Rene LaVigne: LaVigne also serves as president and CEO of Iron Bow, an information technology and services company in Chantilly, Virginia. 

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.